The platform integrates in-silico design with experimental data to accelerate scientific innovation through Models-as-a-Service offering.
Revvity Inc has announced the introduction of Signals Xynthetica, an AI-augmented design platform for molecular and materials discovery that will be integrated into the company’s existing Signals platform as a Models-as-a-Service offering.
The platform combines advanced in-silico generation, predictive modeling, and experimental validation within a single environment, allowing scientific teams to iteratively design, test, and refine candidate molecules. The system is designed to connect AI predictions with laboratory outcomes to drive continuous learning and improvement.
“AI has enormous potential to transform how molecules and materials are designed, but that potential is only realized when models are connected to real scientific workflows and data,” says Kevin Willoe, president of Revvity Signals Software, in a release. “The Signals Xynthetica platform is about operationalizing predictive science that brings in-silico design and experimental validation together in a continuous loop, accelerating discovery across industries.”
Platform Capabilities and Delivery Model
The Signals Xynthetica platform will support multiple in-silico design approaches, including de novo generation, property prediction, and multi-objective optimization. As a Models-as-a-Service offering, the platform enables organizations to access and apply predictive models without building or maintaining AI infrastructure.
The system allows models to be used consistently across projects, refreshed as new data emerges, and evaluated alongside experimental results. According to Revvity, this approach addresses the gap between powerful AI algorithms and their real-world application by embedding models directly into scientific workflows.
The platform targets the shift in life sciences and materials research from trial-and-error experimentation toward predictive, data-driven design. Revvity notes that while AI algorithms continue to advance, their impact remains limited without integration with high-quality experimental data and existing scientific workflows.
Availability and Access
Pre-registration for customers is currently underway, with early access programs planned for the first half of 2026. The platform is positioned as a cornerstone of Revvity’s broader vision for AI-augmented discovery, emphasizing governance, data stewardship, and scientific rigor.
The company expects the offering to enable customers to harness predictive capabilities at scale while maintaining strong oversight of AI model deployment and performance in research environments.
Photo caption: Signals Xynthetica
Photo credit: Revvity
